Veriphi's Mission

Save Lives. Prevent IV Drug Error.
Veriphi is an exciting medical device start-up whose mission is to help save the thousands of lives of people who die annually from intravenous medication error. The company has developed a revolutionary solution to improve medication safety through the verification of intravenous (IV) drugs. By preventing errors and improving governance around medication delivery, Veriphi will save thousands of lives annually and reduce healthcare costs.
Enquire About a Free Trial

Veriphi Stats

Patents

Veriphi has 7 US patents, with 22 granted in other overseas jurisdictions including 2 in China.

Performance

Veriphi’s performance target is 99.9% drug identification accuracy and less than 5% drug concentration error. Veriphi has achieved this in recent trials on a suite of 6 drugs.

Compliance

International laboratory device compliance has been granted.

Cloud Database

The Veriphi cloud database provides a unique level of transparency regarding medication safety & drug delivery.

Investment

Veriphi has raised NZ$9m. With this money Veriphi has achieved commercially viable results, IEC approvals, a sizeable patent portfolio, and engagement with customers. The company is now seeking to secure a NZ$5m Series A investment round.

Global Interest

Veriphi is now poised to expand internationally with interest in New Zealand Australia, and the United States.

Veriphi Milestones

2019
2017
2016
2015
2014
2012
2009

2019

Veriphi achieves regulatory compliance for testing in compounding pharmacies.

2017

100% success in 100 blind trials conducted on 10 anaesthetic drugs using 10 different containers.

2016

100% success in 40 blind trials conducted on 10 anaesthetic drugs using 4 different containers and training data collected at three different temperatures over a week.

2015

Indicative results on verification of 4 drugs in concentrations from 1 to 10 %.

2014

The successful verification of 30/31 drugs in a single flow cell in randomised blind trials.

2012

Initial success with randomised blind trials on 10 drugs.

2009

Work commences in earnest on drug verification

Meet the Team

  • Roger Lampan
    Roger has extensive experience as an entrepreneur, investor and director in various sectors, including staff recruitment, healthcare and medical technology. Roger is currently Chairman of Veriphi and a major investor in the company. He was until recently, Chairman of Geneva Healthcare
  • Roger Lampan
    Roger has extensive experience as an entrepreneur, investor and director in various sectors, including staff recruitment, healthcare and medical technology. Roger is currently Chairman of Veriphi and a major investor in the company. He was until recently, Chairman of Geneva Healthcare
  • Roger Lampan
    Roger has extensive experience as an entrepreneur, investor and director in various sectors, including staff recruitment, healthcare and medical technology. Roger is currently Chairman of Veriphi and a major investor in the company. He was until recently, Chairman of Geneva Healthcare
  • Roger Lampan
    Roger has extensive experience as an entrepreneur, investor and director in various sectors, including staff recruitment, healthcare and medical technology. Roger is currently Chairman of Veriphi and a major investor in the company. He was until recently, Chairman of Geneva Healthcare
  • Roger Lampan
    Roger has extensive experience as an entrepreneur, investor and director in various sectors, including staff recruitment, healthcare and medical technology. Roger is currently Chairman of Veriphi and a major investor in the company. He was until recently, Chairman of Geneva Healthcare